As of September 30, 2026, Zealand Pharma A/S carries a market capitalization of 2.42B, placing it among publicly traded companies globally. Its enterprise value stands at 676.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.42B |
| Enterprise Value | 676.93M |
Zealand Pharma A/S's next confirmed earnings release is scheduled for February 25, 2027.
| Earnings Date | 2/25/2027 |
As of September 30, 2026, Zealand Pharma A/S has 66.59M shares outstanding.
| Shares Outstanding | 66.59M |
As of September 30, 2026, Zealand Pharma A/S trades at a trailing price-to-earnings ratio of 6.15. The price-to-sales ratio is 4.13, and the price-to-book ratio stands at 1.05.
| PE Ratio | 6.15 |
| PS Ratio | 4.13 |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | -12.13 |
| P/OCF Ratio | -12.83 |
As of September 30, 2026, Zealand Pharma A/S trades at an EV/EBITDA multiple of 1.81 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 1.84 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 676.93M versus a market cap of 2.42B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1.10 |
| EV / EBITDA | 1.81 |
| EV / EBIT | 1.84 |
As of September 30, 2026, Zealand Pharma A/S maintains a current ratio of 10.50, meaning it holds 10.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.81, indicating elevated leverage, while an interest coverage ratio of 99.62 demonstrates strong ability to service its debt obligations.
| Current Ratio | 10.50 |
| Quick Ratio | 7.89 |
| Debt / Equity | 2.81 |
| Debt / EBITDA | 0.17 |
| Interest Coverage | 99.62 |
Over the twelve months ended September 30, 2026, Zealand Pharma A/S posted a return on equity (ROE) of 19.07, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.64 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.05, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 18.73, useful for judging operating efficiency across full business cycles. The company generates approximately 1.28M in revenue per employee across its workforce of 481.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | 19.07 |
| Return on Assets (ROA) | 17.05 |
| Return on Invested Capital (ROIC) | 15.64 |
| Return on Capital Employed (ROCE) | 18.73 |
| Revenue Per Employee | 1.28M |
| Employee Count | 481.00 |
Over the twelve months ended September 30, 2026, Zealand Pharma A/S recorded 15.06M in income tax expense. That works out to an effective tax rate of 3.52, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 428.37M, leaving 413.31M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 15.06M |
| Effective Tax Rate | 3.52 |
As of the close on November 17, 2026, Zealand Pharma A/S's stock has declined approximately 55.95% over the past 52 weeks. The 50-day moving average sits at 33.38, while the 200-day moving average is 39.55.
| 52-Week Price Change | -55.95% |
| 50-Day Moving Average | 33.38 |
| 200-Day Moving Average | 39.55 |
Over the twelve months ended September 30, 2026, Zealand Pharma A/S generated 615.03M in revenue and converted that into 413.31M in net income, yielding earnings per share of 5.90. EBITDA reached 374.05M, while operating income came in at 362.90M.
| Revenue | 615.03M |
| Gross Profit | 615.03M |
| Operating Income | 362.90M |
| Pretax Income | 428.37M |
| Net Income | 413.31M |
| EBITDA | 374.05M |
| EBIT | 368.56M |
| Earnings Per Share (EPS) | 5.90 |
As of September 30, 2026, Zealand Pharma A/S holds 1.81B in cash and equivalents against 64.74M in total debt, resulting in a net debt position of -398.21M. Total book value stands at 2.31B, with working capital of 2.17B providing operational flexibility.
| Cash & Cash Equivalents | 1.81B |
| Total Debt | 64.74M |
| Net Debt | -398.21M |
| Equity (Book Value) | 2.31B |
| Book Value Per Share | 34.62 |
| Working Capital | 2.17B |
Zealand Pharma A/S produced -198.21M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -11.63M in capital expenditures, free cash flow totaled -209.84M - equivalent to -3.00 per share.
| Operating Cash Flow | -198.21M |
| Capital Expenditures | -11.63M |
| Free Cash Flow | -209.84M |
| FCF Per Share | -3.00 |
Over the twelve months ended September 30, 2026, Zealand Pharma A/S posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 59.01 and net profit margin of 67.20 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | 59.01 |
| Pretax Margin | 69.65 |
| Profit Margin | 67.20 |
| EBITDA Margin | 60.82 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -8.24: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 6.60, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zealand Pharma A/S shareholders.
| Shareholder Yield | 6.60 |
| FCF Yield | -8.24 |
As of September 30, 2026, Zealand Pharma A/S has an Altman Z-Score of 6.92, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.92 |
Already premium?